Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concomitant 9-valent HPV vaccine and Repevax in adolescents
2009-016218-26Phase 3Completed
- Sponsor
- MSD
- Start
- Jan 2010
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of recombinant human papillomavirus 9-valent vaccine and Adacel Polio in human papillomavirus infection (2 arms), sponsored by MSD. Primary endpoints: Anti-HPV geometric mean titers, Non-inferiority of HPV immune response with concomitant administration and 3 more. Started Jan 2010; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccineAdacel Polio
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2009-016218-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016218-26.